secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-202881
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q2 net loss narrows to $20.6M; cash $630.9M; NUV-868 studies enrolling
--------------------------------------------------------------------------------

- Net loss of $20.6M ($0.09/share) vs $34.9M ($0.16/share) in Q2 2022.
- Cash, cash equivalents and marketable securities of $630.9M as of June 30, 2023.
- R&D expenses decreased to $18.6M from $28.9M, partly due to NUV-422 program termination.
- Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy enrolling.
- Expects to submit IND for first DDC candidate by year end 2023; formed Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523202881/0001193125-23-202881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523202881/d517241d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-202881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer